# Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

> **NCT04305444** · PHASE2 · TERMINATED · sponsor: **Zhejiang DTRM Biopharma** · enrollment: 55 (actual)

## Conditions studied

- Relapsed Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Richter's Transformation

## Interventions

- **DRUG:** DTRM-555

## Key facts

- **NCT ID:** NCT04305444
- **Lead sponsor:** Zhejiang DTRM Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-24
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Despite the efforts of our dedicated team and initial progress, we were unable to secure the necessary financial resources to continue the study. We appreciate the support and participation of all involved.
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305444, "Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04305444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*